Stock Surge#
Hims & Hers Health (NYSE:HIMS) saw its shares jump by 7% after announcing an expansion of its platform. This update allows healthcare providers using Hims & Hers to prescribe weight loss medications from Eli Lilly directly to customers.
New Prescription Options#
The telehealth company revealed that providers can now send prescriptions for Eli Lilly's Zepbound vials and KwikPen, as well as Foundayo, to the LillyDirect pharmacy. This new feature also includes self-pay pricing options for Hims & Hers customers, making it easier for patients to access these FDA-approved weight loss medications.
Strategic Partnerships#
This expansion follows a previous announcement where Hims & Hers partnered with Novo Nordisk to facilitate access to Wegovy injections and pills. The company views these partnerships as part of a strategic shift in its U.S. weight loss business, adapting to the evolving market for FDA-approved GLP-1 treatments, which are designed to aid in weight management.
Comprehensive Care Approach#
Hims & Hers emphasizes that its weight loss membership offers a wide range of support services. Members benefit from 24/7 access to a care team, personalized nutrition guidance, regular clinical check-ins, and peer support within the Hims & Hers Weight Loss community. The company aims to provide a holistic care experience tailored to each customer's individual history, preferences, needs, and goals.